RecruitingNot Applicable

Terraflora Daily Care and Gastrointestinal Health

United States40 participantsStarted 2026-01-12

Plain-language summary

A 12-week, randomized, double-blind, placebo-controlled clinical trial will be conducted evaluating the effectiveness of Enviromedica - Terraflora Daily Care on markers of gastrointestinal function and symptoms.

Who can participate

Age range25 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult males or females age ≥ 25 years
✓. Ability to read and speak English
✓. Dysbiosis (≥3 on GA-Map Dysbiosis Score) on a stool test (GI360 Profile, Doctor's Data, St. Charles, Illinois)

Exclusion criteria

✕. Daily use within the past month of any probiotic or prebiotic supplement
✕. Current diagnosis of inflammatory bowel disease, including Crohn's or ulcerative colitis
✕. Current daily usage of non-steroidal anti-inflammatory drugs (NSAID), proton pump inhibitors (PPI), or antibiotic medications
✕. Current daily tobacco smoker
✕. Known allergies to any substance in the study products
✕. Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks
✕. Current diagnosis of any other chronic health condition (e.g., cancer, chronic kidney disease) deemed clinically contraindicated for the study protocol
✕. Current participation in another clinical trial

What they're measuring

GA-Map Dysbiosis on GI360 Profile

Timeframe: 4 weeks, 12 weeks

Trial details

NCT IDNCT07355634

SponsorOvationLab

Sponsor typeNETWORK

Study typeINTERVENTIONAL

Primary completion2026-06

Contact for this trial

Chris D'Adamo, Ph.D.

240-232-2103 chris@ovationlab.com

View on ClinicalTrials.gov More Gastrointestinal trials